NEW YORK (GenomeWeb) – Caerus Molecular Diagnostics is developing a new single-molecule sequencing technology that promises long reads with low error rates.

The Mountain View, California-based startup, which currently has two employees, is working on proof of concept for its so-called activator sequencing method, which relies on the release of an activator from dNTP that switches on an enzyme.

"We don't have any sequencing data yet, although we hope to be able to get sequencing data in the coming months," said Javier Farinas, the company's founder, CEO, and CTO.